Last reviewed · How we verify

NCT04951557

Setting Benchmarks for Transsphenoidal Resection of Pituitary Adenomas

Status unknown Last updated 7 July 2021
What this trial tests

trial testing Transsphenoidal resection in Pituitary Adenoma in 5,000 participants. Status unknown.

Timeline
31 January 2017
Primary endpoint
31 December 2019
31 December 2022

Quick facts

Lead sponsorUniversitätsklinikum Hamburg-Eppendorf
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment5,000
Start date31 January 2017
Primary completion31 December 2019
Estimated completion31 December 2022
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Universitätsklinikum Hamburg-Eppendorf — full company profile →

Who can join

18 and older, any sex, with Pituitary Adenoma or Pituitary Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To conduct a retrospective multicenter cohort study to define benchmark values for best achievable outcomes following transsphenoidal resection of pituitary adenomas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pituitary Adenoma

Currently open trials in the same condition.

Other Universitätsklinikum Hamburg-Eppendorf trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04951557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing